Details of the Drug-Related molecule(s) Interaction Atlas

AM-92016 Drug Info

COMPOUND II; N-(4-(3-((2-(3,4-Dichlorophenyl)ethyl)methylamino)-2-hydroxypropoxy)phenyl)methanesulfonamide; AM-92016; Bio2_000288; AC1L1CZF; Msaph-2ClPhEA-2-propanol; CBiol_001738; KBioGR_000288; BSPBio_001568; KBioSS_000288; CHEMBL43527; AC1Q3O93; SCHEMBL9655059; KBio3_000575; CHEBI:91532; KBio3_000576; KBio2_002856; KBio2_005424; KBio2_000288; Bio1_000513; HMS1791O10; Bio1_001002; Bio1_000024; HMS1989O10; Bio2_000768; AC-115; IDI1_034038; NCGC00024837-04; NCGC00024837-03; NCGC00024837-02; BRD-A11813248-003-01-6; BRD-A11813248-001-02-8

Cross-matching ID

PubChem CID

133104

CAS Number

CAS 178894-81-0

TTD Drug ID

DMMZNSC

General Information of Drug (ID: DMMZNSC)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Glutamate receptor ionotropic NMDA 1 (NMDAR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cycloserine	DMT1I52	Bacterial infection	1A00-1C4Z	Approved	[2]
D-Serine	DM3YH4I	N. A.	N. A.	Phase 4	[3]
ELIPRODIL	DMIOGZM	Multiple sclerosis	8A40	Phase 2	[4]
NBQX	DMPHZI5	Neurological disorder	6B60	Phase 1	[5]
YM-90K	DMWRT4L	Convulsion	8A68.Z	Discontinued in Phase 2	[6]
SPERMINE	DMD4BFY	N. A.	N. A.	Terminated	[7]
L-689560	DMCVY4U	Neurodegenerative disorder	8A20-8A23	Terminated	[8]
L-698544	DMLRBN1	Alzheimer disease	8A20	Terminated	[9]
DIZOCILPINE	DMMGYXR	Cerebrovascular ischaemia	8B1Z	Terminated	[10]
RPR-104632	DM9L50N	N. A.	N. A.	Terminated	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glutamate receptor ionotropic NMDA 1 (NMDAR1)	TTLD29N	NMDZ1_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Enantiomeric propanolamines as selective N-methyl-D-aspartate 2B receptor antagonists. J Med Chem. 2008 Sep 25;51(18):5506-21.
2	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
3	Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
4	4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000.
5	Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,... J Med Chem. 2001 Sep 13;44(19):3157-65.
6	4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with... Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7.
7	Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem. 2010 May 13;53(9):3611-7.
8	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455).
9	Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
10	Synthesis and evaluation of 6,11-ethanohexahydrobenzo[b]quinolizidines: a new class of noncompetitive N-methyl-D-aspartate antagonists. J Med Chem. 1995 Jun 23;38(13):2483-9.
11	Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem. 2000 Jun 15;43(12):2371-81.